Prevalence and genotypes distribution of virus hepatitis B and hepatitis delta virus in chronic liver diseases in Kazakhstan.
Genotype
Hepatitis B virus
Hepatitis D virus
PCR sequencing
Phylogenetic analysis
delta agent
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
14 Aug 2023
14 Aug 2023
Historique:
received:
22
04
2023
accepted:
08
08
2023
medline:
16
8
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
The geographical distribution of hepatitis B virus (HBV) and hepatitis D virus (HDV) genotypes is uneven and has its own clinical and organizational implications for health systems. Despite the introduction of vaccination and successful antiviral therapy the prevalence of chronic hepatitis B (with or without delta agent) increased over the past 5 years. This study aimed for the first time to investigate the molecular epidemiology of HBV and HDV in Kazakhstan. Total 834 chronic hepatitis B (with or without delta agent) patients were included to the study from November 2017 to June 2019. The material was collected from the regional hepatological сenters from 13 cities of Kazakhstan. Genotyping of HBV/HDV isolates was carried out using phylogenetic analysis of null-binary sequences of Kazakhstani isolates, in comparison with the reference sequences. Nucleotide sequence alignment was performed using the ClustalW algorithm, the "neighbor-joining" method was used for the construction of phylogenetic trees and subsequent analysis. Overall 341 samples were PCR-positive and genotyped for HBV. Comparison and phylogenetic analysis of nucleotide sequences of HBV isolates showed that they were represented by genotypes HBV-D (95.9%), HBV-A (3.5%) and HBV-C (0.6%). At the same time, the identity of the nucleotide sequences of Kazakhstani isolates were: HBV-D (95-100%); HBV-A (97.2-100%) and HBV-C (99%). 256 samples were PCR positive and genotyped for HDV, all of them belonged to genotype 1. This study describes for the first time the molecular epidemiology of HBV and HDV in Kazakhstan. The data obtained expand the knowledge of the global epidemiology of viruses; have potential implications for public health policy and for further clinical research on chronic hepatitis in Kazakhstan. ClinicalTrials.gov NCT05095181 (registered on 27/10/2021).
Sections du résumé
BACKGROUND
BACKGROUND
The geographical distribution of hepatitis B virus (HBV) and hepatitis D virus (HDV) genotypes is uneven and has its own clinical and organizational implications for health systems. Despite the introduction of vaccination and successful antiviral therapy the prevalence of chronic hepatitis B (with or without delta agent) increased over the past 5 years. This study aimed for the first time to investigate the molecular epidemiology of HBV and HDV in Kazakhstan.
METHODS
METHODS
Total 834 chronic hepatitis B (with or without delta agent) patients were included to the study from November 2017 to June 2019. The material was collected from the regional hepatological сenters from 13 cities of Kazakhstan. Genotyping of HBV/HDV isolates was carried out using phylogenetic analysis of null-binary sequences of Kazakhstani isolates, in comparison with the reference sequences. Nucleotide sequence alignment was performed using the ClustalW algorithm, the "neighbor-joining" method was used for the construction of phylogenetic trees and subsequent analysis.
RESULTS
RESULTS
Overall 341 samples were PCR-positive and genotyped for HBV. Comparison and phylogenetic analysis of nucleotide sequences of HBV isolates showed that they were represented by genotypes HBV-D (95.9%), HBV-A (3.5%) and HBV-C (0.6%). At the same time, the identity of the nucleotide sequences of Kazakhstani isolates were: HBV-D (95-100%); HBV-A (97.2-100%) and HBV-C (99%). 256 samples were PCR positive and genotyped for HDV, all of them belonged to genotype 1.
CONCLUSION
CONCLUSIONS
This study describes for the first time the molecular epidemiology of HBV and HDV in Kazakhstan. The data obtained expand the knowledge of the global epidemiology of viruses; have potential implications for public health policy and for further clinical research on chronic hepatitis in Kazakhstan.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05095181 (registered on 27/10/2021).
Identifiants
pubmed: 37580657
doi: 10.1186/s12879-023-08524-1
pii: 10.1186/s12879-023-08524-1
pmc: PMC10426108
doi:
Banques de données
ClinicalTrials.gov
['NCT05095181']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
533Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
World Health Organization. (2016). Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. https://apps.who.int/iris/handle/10665/246177 .
Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (δ/anti-δ) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997–1003. https://doi.org/10.1136/gut.18.12.997 .
doi: 10.1136/gut.18.12.997
pubmed: 75123
pmcid: 1411847
Shirvani-Dastgerdi E. Molecular interactions between hepatitis B virus and delta virus. World J Virol. 2015;4(2):36. https://doi.org/10.5501/wjv.v4.i2.36 .
doi: 10.5501/wjv.v4.i2.36
pubmed: 25964870
pmcid: 4419120
Sakupova GA, Glushkova NYe, Smagul SZhN, Smagulova MA, Kasabekova MK, Khismetova EK. Z.A. Analysis of the long-term dynamics of the incidence of viral hepatitis B and C in the territory of the Republic of Kazakhstan (retrospective analysis) // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, (Vol.23) 4, pp. 163–71. Doi https://doi.org/10.34689/SH.2021.23.4.018 .
Ashimkhanova A, Syssoyev D, Gusmanov A, Yesmembetov K, Yespotayeva A, Abbay A, Nurpeissova A, Sarria-Santamera A, Gaipov A. Epidemiological characteristics of chronic viral Hepatitis in Kazakhstan: data from Unified Nationwide Electronic Healthcare System 2014–2019. Infect drug Resist. 2022;15:3333–46. https://doi.org/10.2147/IDR.S363609 .
doi: 10.2147/IDR.S363609
pubmed: 35782528
pmcid: 9248955
Ashimkhanova A, Syssoyev D, Gusmanov A, Yesmembetov K, Yespotayeva A, Abbay A, …, Gaipov A. Infect Drug Resist. 2022;15:3333–46. https://doi.org/10.2147/IDR.S363609 . Epidemiological Characteristics of Chronic Viral Hepatitis in Kazakhstan: Data from Unified Nationwide Electronic Healthcare System 2014–2019.
Jumabayeva, A., Nersesov, A., Kulzhanov, M., Nefedova, M., Nuraliyeva, G., Rakhimbekova, G., ? Fakhradiyev, I. (2022). Prevalence of Viral Hepatitis B, C, and D in Kazakhstan. Scientific World Journal, 2022. https://doi.org/10.1155/2022/9102565 .
Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32(3):228–36. https://doi.org/10.1055/s-0032-1323628 .
doi: 10.1055/s-0032-1323628
pubmed: 22932971
Taylor JM. (2009). Chapter 3 replication of the Hepatitis Delta Virus RNA genome. Advances in Virus Research. https://doi.org/10.1016/S0065-3527(09)74003-5 .
Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586–92. https://doi.org/10.1016/j.jhep.2015.04.025 .
doi: 10.1016/j.jhep.2015.04.025
pubmed: 25962883
pmcid: 4574953
Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst. 2012;104(10):790–2. https://doi.org/10.1093/jnci/djs168 .
doi: 10.1093/jnci/djs168
pubmed: 22423008
Sitnik R, Pinho JR, Bertolini DA, Bernardini AP, Silva D, L. C., Carrilho FJ. Hepatitis B virus genotypes and precore and core mutants in brazilian patients. J Clin Microbiol. 2004;42(6):2455–60. https://doi.org/10.1128/JCM.42.6.2455-2460.2004 .
doi: 10.1128/JCM.42.6.2455-2460.2004
pubmed: 15184419
pmcid: 427827
Shahinsaz L, Sabahi F, Karimi M, Behzadian F, Alavian SM, Zand V. Detection and genotyping of Hepatitis D Virus from HBsAg positive patients in Iran using RT-PCR. Iran J Biotechnol. 2006;4(3):174–9.
Genotyping tool - help. (n.d.). https://www.ncbi.nlm.nih.gov/projects/genotyping/help.html .
Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4(4):406–25. https://doi.org/10.1093/oxfordjournals.molbev.a040454 .
doi: 10.1093/oxfordjournals.molbev.a040454
pubmed: 3447015
Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci USA. 2004;101(30):11030–5. https://doi.org/10.1073/pnas.0404206101 .
doi: 10.1073/pnas.0404206101
pubmed: 15258291
pmcid: 491989
Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427–34. https://doi.org/10.3748/wjg.v20.i18.5427 .
doi: 10.3748/wjg.v20.i18.5427
pubmed: 24833873
pmcid: 4017058
Lin CL, Kao JH. (2011). The clinical implications of hepatitis B virus genotype: recent advances. Journal of Gastroenterology and Hepatology (Australia). Blackwell Publishing. https://doi.org/10.1111/j.1440-1746.2010.06541.x .
Tanwar S, Dusheiko G. Is there any value to hepatitis B virus genotype analysis? Curr Gastroenterol Rep. 2012;14(1):37–46. https://doi.org/10.1007/s11894-011-0233-5 .
doi: 10.1007/s11894-011-0233-5
pubmed: 22105466
Liu Z, Zhang Y, Xu M, Li X, Zhang Z. Distribution of hepatitis B virus genotypes and subgenotypes: a meta-analysis. Medicine. 2021;100(50):e27941. https://doi.org/10.1097/MD.0000000000027941 .
doi: 10.1097/MD.0000000000027941
pubmed: 34918643
pmcid: 8678021
Liu CJ, Kao JH. (2013). Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes a to J. Seminars in Liver Disease. https://doi.org/10.1055/s-0033-1345716 .
Velkov S, Ott JJ, Protzer U, Michler T. The Global Hepatitis B Virus genotype distribution approximated from available genotyping data. Genes. 2018;9(10):495. https://doi.org/10.3390/genes9100495 .
doi: 10.3390/genes9100495
pubmed: 30326600
pmcid: 6210291
Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523–32. https://doi.org/10.1016/j.jhep.2020.04.008 .
doi: 10.1016/j.jhep.2020.04.008
pubmed: 32335166
pmcid: 7438974
Le Gal F, Brichler S, Drugan T, Alloui C, Roulot D, Pawlotsky JM, Dény P, Gordien E. Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains. Hepatology (Baltimore MD). 2017;66(6):1826–41. https://doi.org/10.1002/hep.29574 .
doi: 10.1002/hep.29574
pubmed: 28992360
Niro GA, Ferro A, Cicerchia F, Brascugli I, Durazzo M. Hepatitis delta virus: from infection to new therapeutic strategies. World J Gastroenterol. 2021;27(24):3530–42. https://doi.org/10.3748/wjg.v27.i24.3530 .
doi: 10.3748/wjg.v27.i24.3530
pubmed: 34239267
pmcid: 8240063